Periprostatic adipocytes act as a driving force for prostate cancer progression in obesity

Victor Laurent(Centre National de la Recherche Scientifique), Adrien Guérard(Centre National de la Recherche Scientifique), Catherine Mazerolles(Centre Hospitalier Universitaire de Toulouse), Sophie Le Gonidec(Université Toulouse III - Paul Sabatier), Aurélie Toulet(Centre National de la Recherche Scientifique), Laurence Nieto(Centre National de la Recherche Scientifique), Falek Zaidi(Centre Hospitalier Universitaire de Toulouse), Bilal Majed(Bibliothèque d'Agglomération du Pays de Saint-Omer), David Garandeau(Centre National de la Recherche Scientifique), Youri Socrier(Centre Hospitalier Universitaire de Toulouse), Muriel Golzio(Centre National de la Recherche Scientifique), Thomas Cadoudal(Université Toulouse III - Paul Sabatier), Karima Chaoui(Centre National de la Recherche Scientifique), Cédric Dray(Université Toulouse III - Paul Sabatier), Bernard Monsarrat(Centre National de la Recherche Scientifique), Odile Burlet‐Schiltz(Centre National de la Recherche Scientifique), Yuan Yuan Wang(Centre National de la Recherche Scientifique), Bettina Couderc(Université Toulouse III - Paul Sabatier), Philippe Valet(Université Toulouse III - Paul Sabatier), Bernard Malavaud(Université Toulouse III - Paul Sabatier), Catherine Muller(Centre National de la Recherche Scientifique)
Nature Communications
January 12, 2016
Cited by 287Open Access
Full Text

Abstract

Obesity favours the occurrence of locally disseminated prostate cancer in the periprostatic adipose tissue (PPAT) surrounding the prostate gland. Here we show that adipocytes from PPAT support the directed migration of prostate cancer cells and that this event is strongly promoted by obesity. This process is dependent on the secretion of the chemokine CCL7 by adipocytes, which diffuses from PPAT to the peripheral zone of the prostate, stimulating the migration of CCR3 expressing tumour cells. In obesity, higher secretion of CCL7 by adipocytes facilitates extraprostatic extension. The observed increase in migration associated with obesity is totally abrogated when the CCR3/CCL7 axis is inhibited. In human prostate cancer tumours, expression of the CCR3 receptor is associated with the occurrence of aggressive disease with extended local dissemination and a higher risk of biochemical recurrence, highlighting the potential benefit of CCR3 antagonists in the treatment of prostate cancer.


Related Papers

No related papers found

Powered by citation graph analysis